Pharmacogenetics of new analgesics.
- Authors
- LΓΆtsch, JΓΆrn; Geisslinger, Gerd
- Year
- 2011
- Journal
- British journal of pharmacology
- PMID
- 20942817
- DOI
- 10.1111/j.1476-5381.2010.01074.x
- PMCID
- PMC3101608
Patient phenotypes in pharmacological pain treatment varies between individuals, which could be partly assigned to their genotypes regarding the targets of classical analgesics (OPRM1, PTGS2) or associated signalling pathways (KCNJ6). Translational and genetic research have identified new targets, for which new analgesics are being developed. This addresses voltage-gated sodium, calcium and potassium channels, for which SCN9A, CACNA1B, KCNQ2 and KCNQ3, respectively, are primary gene candidates because they code for the subunits of the respective channels targeted by analgesics currently in clinical development. Mutations in voltage gated transient receptor potential (TRPV) channels are known from genetic pain research and may modulate the effects of analgesics under development targeting TRPV1 or TRPV3. To this add ligand-gated ion channels including nicotinic acetylcholine receptors, ionotropic glutamate-gated receptors and ATP-gated purinergic P2X receptors with most important subunits coded by CHRNA4, GRIN2B and P2RX7. Among G protein coupled receptors, Ξ΄-opioid receptors (coded by OPRD1), cannabinoid receptors (CNR1 and CNR2), metabotropic glutamate receptors (mGluR5 coded by GRM5), bradykinin B(1) (BDKRB1) and 5-HT(1A) (HTR1A) receptors are targeted by new analgesic substances. Finally, nerve growth factor (NGFB), its tyrosine kinase receptor (NTRK1) and the fatty acid amide hydrolase (FAAH) have become targets of interest. For most of these genes, functional variants have been associated with neuro-psychiatric disorders and not yet with analgesia. However, research on the genetic modulation of pain has already identified variants in these genes, relative to pain, which may facilitate the pharmacogenetic assessments of new analgesics. The increased number of candidate pharmacogenetic modulators of analgesic actions may open opportunities for the broader clinical implementation of genotyping information.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Advances in Electrophysiological Research. | 2015 | 26259089 |
| Family-based genome-wide association study of frontal ΞΈ oscillations identifies potassium channel gene KCNJ6. | 2012 | 22554406 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Knowledge of the genetics of human pain gained over the last decade from next-generation sequencing. | Kringel D et al. | β | 2025 | β |
| Artificial intelligence and machine learning in clinical pharmacological research. | Mayer B et al. | β | 2024 | β |
| The genetic variant SLC2A1 -rs1105297 is associated with the differential analgesic response to a glucose-based treatment in newborns. | Farinella R et al. | β | 2024 | β |
| Multi-animal-model study reveals mutations in neural plasticity and nociception genes linked to excessive alcohol drinking. | Muir WM et al. | β | 2023 | β |
| Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions. | McDonnell JM et al. | β | 2023 | β |
| An active ingredient isolated from <i>Ganoderma lucidum</i> promotes burn wound healing via TRPV1/SMAD signaling. | Jiao C et al. | β | 2022 | β |
| Computational Functional Genomics-Based AmpliSeqβ’ Panel for Next-Generation Sequencing of Key Genes of Pain. | Kringel D et al. | β | 2021 | β |
| Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review. | Furgiuele A et al. | β | 2021 | β |
| Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence. | Fang CP et al. | β | 2020 | β |
| Genetics and Opioids: Towards More Appropriate Prescription in Cancer Pain. | Bugada D et al. | β | 2020 | β |
| Machine-Learned Association of Next-Generation Sequencing-Derived Variants in Thermosensitive Ion Channels Genes with Human Thermal Pain Sensitivity Phenotypes. | LΓΆtsch J et al. | β | 2020 | β |
| Effects of continuous theta-burst stimulation of the primary motor and secondary somatosensory areas on the central processing and the perception of trigeminal nociceptive input in healthy volunteers. | Annak O et al. | β | 2019 | β |
| [Generating knowledge from complex data sets in human experimental pain research]. | LΓΆtsch J et al. | β | 2019 | β |
| A machine-learned analysis of human gene polymorphisms modulating persisting pain points to major roles of neuroimmune processes. | Kringel D et al. | β | 2018 | β |
| Computational functional genomics-based approaches in analgesic drug discovery and repurposing. | Lippmann C et al. | β | 2018 | β |
| Experimental Drugs for Neuropathic Pain. | Salat K et al. | β | 2018 | β |
| Effect of endocannabinoid degradation on pain: role of FAAH polymorphisms in experimental and postoperative pain in women treated for breast cancer. | Cajanus K et al. | β | 2016 | β |
| Advances in Electrophysiological Research. | Kamarajan C et al. | β | 2015 | β |
| Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children. | Anderson BJ et al. | β | 2015 | β |
| Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects. | Pickering G | β | 2014 | β |
| Confronting the challenges of effective pain management in children following tonsillectomy. | Lauder G et al. | β | 2014 | β |
| New investigational drugs for the treatment of neuropathic pain. | SaΕat K et al. | β | 2014 | β |
| No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids. | Hu SS et al. | β | 2014 | β |
| Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics. | Sousa-Valente J et al. | β | 2014 | β |
| Why is there no morphine concentration-response curve for acute pain? | Anderson BJ et al. | β | 2014 | β |
| Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research. | Oertel BG et al. | β | 2013 | β |
| Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. | Weerts EM et al. | β | 2013 | β |
| Modeling the influence of the A118G polymorphism in the OPRM1 gene and of noxious stimulation on the synergistic relation between propofol and remifentanil: sedation and analgesia in endoscopic procedures. | Borrat X et al. | β | 2013 | β |
| Pharmacogenetics of analgesic drugs. | Cregg R et al. | β | 2013 | β |
| Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. | Hajj A et al. | β | 2013 | β |
| A future without chronic pain: neuroscience and clinical research. | Borsook D | β | 2012 | β |
| Family-based genome-wide association study of frontal ΞΈ oscillations identifies potassium channel gene KCNJ6. | Kang SJ et al. | β | 2012 | β |
| Pharmacogenetics and anaesthesia: the value of genetic profiling. | Landau R et al. | β | 2012 | β |
| Potassium channel modulators as possible treatment for pain: patent highlight. | Abdel-Magid AF | β | 2012 | β |
| Ask the Experts: What do we know (and not know) about prescription opioid misuse in the context of chronic pain management? | Zacny J | β | 2011 | β |
| Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches. | GavΓ©riaux-Ruff C et al. | β | 2011 | β |